Amgen (AMGN) Convertible Debt (2009 - 2010)

Amgen (AMGN) posted quarterly Convertible Debt of $2.2 billion for Q1 2010, down 51.22% on a QoQ basis from $4.5 billion in Q4 2009.

Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends

Amgen (AMGN) has reported Convertible Debt for 2 consecutive years, with $2.2 billion the latest figure, recorded in Q1 2010.

In Q1 2010, Convertible Debt changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2010 stood at $2.2 billion (changed N/A YoY), while the FY2009 annual figure was $4.5 billion, changed N/A from the prior year.
Convertible Debt came in at $2.2 billion for Q1 2010 at Amgen, down from $4.5 billion in the prior quarter.
The five-year high for Convertible Debt was $4.5 billion in Q4 2009, with the low at $2.2 billion in Q1 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn

Download Data